NASDAQ:BIIB - Biogen Stock Price, Forecast & News

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen announced that its board has approved a share buyback program on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its shares are undervalued.

Biogen Inc (NASDAQ:BIIB) issued its earnings results on Thursday, January, 30th. The biotechnology company reported $8.34 EPS for the quarter, topping analysts' consensus estimates of $8.02 by $0.32. The biotechnology company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.51 billion. Biogen had a net margin of 40.96% and a return on equity of 46.51%. Biogen's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $6.99 earnings per share. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Biogen.

Biogen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $31.50-33.50 for the period, compared to the Thomson Reuters consensus estimate of $31.98. The company issued revenue guidance of ~$14.0-14.3 billion, compared to the consensus revenue estimate of $13.85 billion.

34 brokers have issued 12-month price objectives for Biogen's stock. Their forecasts range from $230.00 to $410.00. On average, they anticipate Biogen's stock price to reach $316.69 in the next twelve months. This suggests that the stock has a possible downside of 5.9%. View Analyst Price Targets for Biogen.

34 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 20 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

News articles about BIIB stock have been trending somewhat negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biogen earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Biogen.

Biogen saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,600,000 shares, a decline of 16.9% from the January 15th total of 4,330,000 shares. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is currently 2.0 days. Currently, 2.0% of the company's shares are sold short. View Biogen's Current Options Chain.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Walt Disney (DIS) and Boeing (BA).

Biogen's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (4.56%), Renaissance Technologies LLC (2.63%), Geode Capital Management LLC (1.90%), AQR Capital Management LLC (1.51%), Bank of New York Mellon Corp (1.22%) and Capital World Investors (1.05%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Alliancebernstein L.P., Jackson Square Partners LLC, AQR Capital Management LLC, FMR LLC, State Street Corp, Assenagon Asset Management S.A. and Massachusetts Financial Services Co. MA. Company insiders that have sold Biogen company stock in the last year include Brian S Posner and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., Bank of New York Mellon Corp, Fred Alger Management LLC, First Trust Advisors LP, Samlyn Capital LLC and Marshall Wace North America L.P.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $336.64.

Biogen has a market capitalization of $58.60 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.View Additional Information About Biogen.

The official website for Biogen is http://www.biogen.com/.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]